Get rid of a troublesome double-chin with no surgery!

Kybella, also known as deoxycholic acid, is a prescription-based product designed to treat fullness beneath the chin (more commonly known as the “double-chin”). Sometimes diet and exercise may not give you the results you’re looking for. Since deoxycholic acid is a naturally occurring substance regularly found in the body to aid in digestion, Kybella is potentially a great natural solution to get rid of that extra fat!

Once destroyed, these cells can no longer store or accumulate fat, so further treatment is not expected once you reach your desired aesthetic goal.

Kybella logo

The Procedure

Kybella is a series of injections administered in the submental (under the chin) area over a series of visits. Each visit is approximately 15-20 minutes and then you can resume your normal activities. While unlikely, bruising is possible and should be considered when receiving any injections. Once the desired result is achieved, no more treatment is required.

Prior to injection, a consultation is scheduled to determine if Kybella is the appropriate solution.

If Kybella is the appropriate path forward, the injections will be performed in our on-site surgical suite. This creates the optimal environment for injections – allowing for precise lighting and maximizing patient comfort.

A temporary “dot-matrix” injection guide (very similar to the temporary “tattoos” children play with) will be applied to the submental area skin. The dots that fall within the delineated area of injection (marked off with temporary pencil earlier) will be the injection sites.

Topical anesthetic is applied to the skin to minimize potential pain. Temporary marking pencil is used to delineate the area of injections as well mark off areas to avoid. This insures a precise and detailed result that is customized to your anatomy.

Watch a video of the Kybella Procedure

Patient before Kybella


Patient after Kybella treatment


Multiple treatments may be needed to achieve final result.  Time after treatment is approximately 4 months.

How does the Kybella treatment work?

Kybella works by destroying fat cells (lipocytes). Once these cells are destroyed (lipolysis), fat is no longer able to be stored in the area as the “fat containers” are gone.

Do I need multiple treatments?

Our private complimentary consultation will determine the number of sessions that you need based on your specific physiology and personal desires. You may receive from 1 to 4 treatments, no less than 6 weeks apart.

Are their side effects to Kybella?

Side effects are rare and in all cases temporary. The most common side effects include swelling, bruising, pain, numbness, redness and areas of hardness. For more information, please see below and on the Kybella website.







Results are after multiple treatments of Kybella.  Individual results may vary.

Before receiving Kybella™ Injections

  • KYBELLA™ should not be injected if there is an infection in the treatment area.
  • Before receiving KYBELLA™, patients should tell their healthcare provider about all of their medical conditions, including if they:
    • have had or plan to have surgery on the face, neck, or chin
    • have had cosmetic treatments on the face, neck, or chin
    • have had or have medical conditions in or near the neck area
    • have had or have trouble swallowing
    • have bleeding problems or are taking blood thinners
    • are pregnant or plan to become pregnant. It is not known if KYBELLA™ will harm an unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if KYBELLA™ passes into your breast milk.
  • Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. They should especially tell their healthcare provider if they take a medicine that prevents the clotting of blood (antiplatelet or anticoagulant medicine).
  • Patients should be advised to inform their healthcare provider if they develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or if any existing symptom worsens.
  • KYBELLA™ (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
  • The safe and effective use of KYBELLA™for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

Important Kybella™ Safety Information

  • KYBELLA™ should only be administered by a trained healthcare professional.
  • KYBELLA™ is contraindicated in the presence of infection at the injection sites.
  • Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage.
  • Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported during clinical trials.
  • To avoid the potential for nerve injury, KYBELLA™ should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
  • All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days).
  • Difficulty swallowing (dysphagia) occurred in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials.
  • Avoid use of KYBELLA™ in these patients as current or prior history of dysphagia may exacerbate the condition.
  • In clinical trials, 72% of subjects treated with KYBELLA™ experienced injection site hematoma/bruising. KYBELLA™ should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
  • To avoid the potential of tissue damage, KYBELLA™should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
  • The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.